Prescription Drugs & Other Medical Products

This study examines relationships between indicators of economic opportunity and the prevalence of prescription opioids and substance use in the United States. We have three primary findings:

This brief describes the research methods used to produce the findings in Substance Use, the Opioid Epidemic, and Child Welfare Caseloads: A Mixed Methods Study. It is a part of a series of briefs that discuss different aspects and issues surrounding the relationship between substance use disorders and the child welfare system.

This study examined the relationship between parental substance misuse and child welfare caseloads, which began rising in 2012 after more than a decade of decline.

To combat the public health crisis associated with the opioid overdose epidemic, HHS will host an Opioid Code-a-Thon on December 6-7, 2017 to develop data driven solutions to combat the opioid epidemic.  This Data Brief presents an overview of the data sources that could be leveraged to study the opioid crisis within each of the five HHS strategic areas, highlights some of the key res

Medicare Part B covers infusible and injectable drugs and biologics administered in physician offices and hospital outpatient departments; as well as certain other drugs required by law provided by suppliers such as pharmacies The Part B payment method provides weak incentives for physicians to consider value – that is choose the lowest cost therapy to effectively treat a patient.

Key findings • Expenditures on prescription drugs are rising and are projected to continue to rise faster than overall health spending thereby increasing this sector’s share of health care spending.

 

In response to the growing opioid epidemic, HHS announced a three-pronged initiative in March 2015 to: (1) improve opioid prescribing practices; (2) increase access to naloxone for overdose management; and (3) expand medication-assisted treatment (MAT) to reduce opioid dependence.

ASPE ISSUE BRIEF Steven Sheingold, Nguyen Nguyen, and Andre Chappel Disclaimer Persons with disabilities having problems accessing this document may call (202) 690-6870 for assistance.